Has Mary Joubert received payments from drug or device companies?

Yes. Drug and device makers reported $7,387 in general payments to Mary Joubert across 415 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Joubert did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Joubert come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Joubert

Infectious Disease · Slidell, LANPI 1730148677

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,924 and has fallen 87.5% since, to $240 in 2024.

$7,387in general payments, 2019–2025

Across 415 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Viiv Healthcare Company$1K
Gilead$1K
Merck$715
Regeneron Healthcare Solutions, Inc.$484
AbbVie$443
Insmed, Inc.$383
plus $3K from 34 others

What the payments were for

Speaking & faculty fees$160%
Food & beverage$7,29799%
Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Viiv Healthcare Company	77	$1,435
Gilead	67	$1,096
Merck	48	$715
Regeneron Healthcare Solutions, Inc.	19	$484
AbbVie(2 entities)	31	$443
Insmed, Inc.	24	$383
Sanofi	12	$327
Grifols USA, LLC	12	$232
Johnson & Johnson(2 entities)	10	$205
Boehringer Ingelheim	12	$204
Paratek Pharmaceuticals, Inc.	11	$195
Mylan Specialty L.p.	11	$175
AstraZeneca(2 entities)	9	$151
Theratechnologies Inc.	8	$145
Electromed, Inc.	8	$129
Baxter Healthcare	5	$114
Astellas Pharma US Inc	3	$112
Tetraphase Pharmaceuticals, Inc.	5	$89
Melinta Therapeutics, LLC	5	$81
EMD Serono, Inc.	4	$77
Shionogi Inc	3	$66
Cumberland Pharmaceuticals, Inc.	4	$63
Amgen	3	$53
Actelion Pharmaceuticals US, Inc.	2	$49
Bayer	2	$35
Novartis	2	$35
Sanofi Pasteur Inc.	2	$35
Pfizer	2	$33
Napo Pharmaceuticals Inc	2	$32
Circassia Inc.	2	$27
Nuwellis, Inc.	1	$24
GSK	1	$21
Tactile Systems Technology Inc	1	$20
Advanced Respiratory, Inc	1	$17
Jazz Pharmaceuticals Inc.	1	$16
Phadia US Inc.	1	$15
Resmed Corp	1	$15
La Jolla Pharmaceutical Company	1	$15
Philips North America LLC	1	$13
Apria Healthcare LLC	1	$13

How this compares

$7,387 in reported general payments places this provider in the 80th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	40	$158,432
DescovyEmtricitabine/Tenofov Alafenam	47	$104,572
TivicayDolutegravir Sodium	27	$95,787
TriumeqAbacavir/Dolutegravir/Lamivudi	20	$73,157
OdefseyEmtricitab/Rilpiviri/Tenof Ala	16	$69,752
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	13	$49,697
JulucaDolutegravir/Rilpivirine	12	$41,133
Efavirenz	11	$936
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	11	$549
Acyclovir	16	$311
Amlodipine Besylate	13	$37
Escitalopram Oxalate	13	$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy, Descovy, Genvoya	$1,096	$312,701100 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca	$1,435	$210,07759 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 infectious disease providers in Louisiana.